Cancer Blood Test Fails Key Trial

A significant clinical trial conducted in Britain has yielded disappointing results for a novel blood test designed for early cancer detection. The study, which involved 142,000 healthy adults aged 50 to 77, found no reduction in cancers diagnosed at Stage 3 or Stage 4.

The test, known as Galleri, was developed by Grail and aims to detect minute fragments of cancer DNA circulating in the blood, screening for more than 50 cancer types. Despite its potential to save lives by catching cancer earlier, the trial's primary endpoint was not achieved.

Grail executives acknowledged the trial did not meet its main objective but pointed to other positive outcomes, including a reduction in Stage 4 cancer diagnoses, as encouraging signs. The company intends to present more detailed findings at an upcoming cancer conference.

While Galleri is already available in the U.S. for $949 and has seen nearly half a million sales, it is not yet FDA-approved. Recent legislative changes in the U.S. could pave the way for Medicare coverage, but regulatory approval remains a hurdle, potentially influenced by these trial outcomes.